Category Archives: News

International Society of Atopic Dermatitis Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin

International Society of Atopic Dermatitis Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin NEWS PROVIDED BY Alphyn Biologics October 26, 2024, 19:30 ET N432_Neal-KOLLER_Itch-Reduction-and-Quality-of-Life-Improvement-in-AD-for-First-Human-Use-of-Zabalfin CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel

2024 European Association of Dermatology and Venerology (EADV) Poster Presentation: Itch Reduction and Quality of Life Improvement in AD for First Human Use of Zabalafin Hydrogel NEWS PROVIDED BY Alphyn Biologics September 28, 2024, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Society for Pediatric Dermatology Poster Presentation: First-in-Human Phase 2 Trial of Zabalafin Hydrogel (AB-101a) – Itch and Quality of Life Pediatric Results

Society for Pediatric Dermatology Poster Presentation: First-in-Human Phase 2 Trial of Zabalafin Hydrogel (AB-101a) – Itch and Quality of Life Pediatric Results NEWS PROVIDED BY Alphyn Biologics July 8, 2024, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Masters of Pediatric Dermatology Symposium Poster Presentation: First in Human Phase 2 Trial of Zabalafin (AB-101) – Interim Results

Masters of Pediatric Dermatology Symposium Poster Presentation: First in Human Phase 2 Trial of Zabalafin (AB-101) – Interim Results NEWS PROVIDED BY Alphyn Biologics February 8, 2023, 17:00 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Clinical Trials Arena: Alphyn prepares for two global trials in atopic dermatitis

Clinical Trials Arena: Alphyn prepares for two global trials in atopic dermatitis by Urtė Fultinavičiūtė NEWS PROVIDED BY Alphyn Biologics July 26, 2023 Alphyn is planning to open sites in the US, Canada, Europe and Australia. Read the Clinical Trials Arena article here. CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas…

Healio: Interim results show AB-101a significantly controls atopic dermatitis skin bacteria

Healio: Interim results show AB-101a significantly controls atopic dermatitis skin bacteria by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 17, 2023 80% of patients achieved an itch score improvement of 4 points or more. 90% of patients achieved EASI 50 and 44% achieved EASI 75. Read the Healio article here. CONTACTS   Corporate: Neal…

Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection

Dermatology Times: Alphyn Biologics Shares Positive Interim Results of Phase 2a Trial for AD With Secondary Bacterial Infection Kaitlyn Bader, Senior Editor NEWS PROVIDED BY Alphyn Biologics July 14, 2023 AB-101a is a new topical treatment being investigated for mild, moderate, and severe atopic dermatitis and its immune system component. Read the Dermatology Times article…

Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis

Healio: AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 14, 2023 53.3% of pediatric patients treated with AB-101a achieved a 1-point decrease in IGA vs. 0% of those treated with vehicle. This outcome was also seen in 60% of…

Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis

Society for Pediatric Dermatology Poster Presentation: Phase 2a Trial of Topical Therapeutic for Mild, Moderate, and Severe Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics July 13, 2023, 19:30 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis

Dermatology Times: Topical Therapeutic Shows Significant Improvement in Mild-to-Moderate Atopic Dermatitis Heather Raglin, Editor NEWS PROVIDED BY Alphyn Biologics July 11, 2023 Alphyn Biologics announced positive results from their Phase 2a trial of AB-101a will lead to a multinational Phase 2b trial soon. Read the Dermatology Times article here. CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com…